JP2013538047A5 - - Google Patents

Info

Publication number

JP2013538047A5

JP2013538047A5 JP2013519785A JP2013519785A JP2013538047A5 JP 2013538047 A5 JP2013538047 A5 JP 2013538047A5 JP 2013519785 A JP2013519785 A JP 2013519785A JP 2013519785 A JP2013519785 A JP 2013519785A JP 2013538047 A5 JP2013538047 A5 JP 2013538047A5

Authority

JP

Japan

Prior art keywords

cat

dlg1

antisense

cur

cells

Prior art date

2011-07-13

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 102100024099 Disks large homolog 1 Human genes 0.000 description 13
• 108091034117 Oligonucleotide Proteins 0.000 description 12
• 239000000074 antisense oligonucleotide Substances 0.000 description 12
• 238000012230 antisense oligonucleotides Methods 0.000 description 12
• 239000002609 medium Substances 0.000 description 7
• 108020000948 Antisense Oligonucleotides Proteins 0.000 description 6
• 239000001963 growth medium Substances 0.000 description 6
• 108020005544 Antisense RNA Proteins 0.000 description 5
• 230000008685 targeting Effects 0.000 description 5
• 230000000692 anti-sense effect Effects 0.000 description 4
• 238000002474 experimental method Methods 0.000 description 4
• 108020004999 messenger RNA Proteins 0.000 description 4
• 239000000243 solution Substances 0.000 description 4
• UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
• 238000003556 assay Methods 0.000 description 3
• 230000014509 gene expression Effects 0.000 description 3
• 239000000203 mixture Substances 0.000 description 3
• 238000003753 real-time PCR Methods 0.000 description 3
• 239000002356 single layer Substances 0.000 description 3
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
• 239000012594 Earle’s Balanced Salt Solution Substances 0.000 description 2
• 239000012097 Lipofectamine 2000 Substances 0.000 description 2
• 239000012124 Opti-MEM Substances 0.000 description 2
• 229930182555 Penicillin Natural products 0.000 description 2
• JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
• JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
• 239000002299 complementary DNA Substances 0.000 description 2
• 208000002854 epidermolysis bullosa simplex superficialis Diseases 0.000 description 2
• 238000011534 incubation Methods 0.000 description 2
• 229940049954 penicillin Drugs 0.000 description 2
• 238000010839 reverse transcription Methods 0.000 description 2
• 229960005322 streptomycin Drugs 0.000 description 2
• 238000001890 transfection Methods 0.000 description 2
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
• 229920000742 Cotton Polymers 0.000 description 1
• 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
• 101001053984 Homo sapiens Disks large homolog 1 Proteins 0.000 description 1
• 238000002123 RNA extraction Methods 0.000 description 1
• 238000010802 RNA extraction kit Methods 0.000 description 1
• 206010052428 Wound Diseases 0.000 description 1
• 208000027418 Wounds and injury Diseases 0.000 description 1
• 238000000540 analysis of variance Methods 0.000 description 1
• 230000009286 beneficial effect Effects 0.000 description 1
• 239000013553 cell monolayer Substances 0.000 description 1
• 238000003633 gene expression assay Methods 0.000 description 1
• 238000010842 high-capacity cDNA reverse transcription kit Methods 0.000 description 1
• 102000048070 human DLG1 Human genes 0.000 description 1
• 238000000034 method Methods 0.000 description 1
• 239000007758 minimum essential medium Substances 0.000 description 1
• 238000010149 post-hoc-test Methods 0.000 description 1
• 239000000523 sample Substances 0.000 description 1
• 239000008223 sterile water Substances 0.000 description 1